NewcelX (NCEL) Other Accumulated Expenses (2019 - 2025)
NewcelX (NCEL) posted quarterly Other Accumulated Expenses of $434069.0 for Q2 2025, down 69.44% year-over-year from $1.4 million in Q2 2024, and up 39.45% quarter-over-quarter from $311278.0 in Q4 2024.
NewcelX (NCEL) Other Accumulated Expenses (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Other Accumulated Expenses for 7 consecutive years, with $434069.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Other Accumulated Expenses fell 69.44% year-over-year to $434069.0; the TTM figure through Jun 2025 stood at $434069.0 (down 69.44% YoY), while the FY2024 annual figure was $311278.0, down 81.16% from the prior year.
- Other Accumulated Expenses climbed to $434069.0 in Q2 2025 per NCEL's latest filing, from $311278.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.7 million in Q4 2023 and bottomed at $4107.0 in Q4 2022.
- Historically, Other Accumulated Expenses has averaged $683040.4 across 5 years, with a median of $665648.0 in 2021.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses plunged 83.16% — and 2023, when it jumped 40130.58%.
- NewcelX's Other Accumulated Expenses stood at $6877.0 in 2021, then tumbled by 40.28% to $4107.0 in 2022, then surged by 40130.58% to $1.7 million in 2023, then tumbled by 81.16% to $311278.0 in 2024, then jumped by 39.45% to $434069.0 in 2025.
- Business Quant data shows NCEL's Other Accumulated Expenses at $434069.0 in Q2 2025, $311278.0 in Q4 2024, and $1.4 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 434,069.00 |
| Dec 31, 2024 | 311,278.00 |
| Jun 30, 2024 | 1.42 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Jun 30, 2023 | 986,437.00 |
| Dec 31, 2022 | 4,107.00 |
| Jun 30, 2022 | 666,449.00 |
| Dec 31, 2021 | 6,877.00 |
| Jun 30, 2021 | 665,648.00 |
| Dec 31, 2020 | 40,842.00 |
| Dec 31, 2019 | 12,391.00 |